Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_assertion type Assertion NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_head.
- NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_assertion description "[Moreover, LY294002, a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinases (PI3K), was selected to pretreat ovarian cancer cells to confirm whether PI3K/Akt signaling is involved in this event.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_provenance.
- NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_assertion evidence source_evidence_literature NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_provenance.
- NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_assertion SIO_000772 25340291 NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_provenance.
- NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_assertion wasDerivedFrom befree-2016 NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_provenance.
- NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_assertion wasGeneratedBy ECO_0000203 NP1232019.RAFChJ1wEtNuXC8MfgDLswXG1EjAHp-Wvli062SH96JfM130_provenance.